# Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

> **NCT03052751** · PHASE2 · COMPLETED · sponsor: **UCB Biopharma S.P.R.L.** · enrollment: 43 (actual)

## Conditions studied

- Myasthenia Gravis

## Interventions

- **DRUG:** UCB7665
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03052751
- **Lead sponsor:** UCB Biopharma S.P.R.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-15
- **Primary completion:** 2018-05-31
- **Final completion:** 2018-08-06
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2021-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03052751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03052751, "Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03052751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*